The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
See Article on Page 1913 Supported by NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (R01DK106419), and DOD PRCRP (CA170674P2) to R.L. Potential conflict of interest: LA holds patents for Hepascore. The global epidemic of obesity has led to the rise of nonalcoholic fatty liver disease (NAFLD) as a significant cause of cirrhosis, end‐stage liver disease, and need for liver transplantation.1 NAFLD is common, with a global estimate of 25% of adults2; however, only a small proportion will progress to cirrhosis and develop liver‐related morbidity. As with other chronic liver diseases, the severity of underlying liver fibrosis aids prediction of outcome, with patients with bridging fibrosis or cirrhosis being at greatest risk of future liver‐related morbidity.3 Nonetheless, key questions remain largely unanswered, including what proportion of subjects develop progressive disease, how fast this occurs, and how to identify and monitor these individuals. These questions are becoming increasingly relevant given that efficacious drug treatments are likely to become available within the next few years and will need to be targeted at those with greatest risk of disease‐related morbidity. In this context, Sanyal and colleagues explore in this issue of Hepatology the progression of liver disease and predictors of fibrosis progression and decompensation, as well as potential monitoring strategies in 475 patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis or compensated cirrhosis.4 Notably, 68% of patients with cirrhosis had a baseline hepatic venous pressure gradient (HPVG) measurement of ≥10 mm Hg, demonstrating that the majority had clinically significant portal hypertension at study entry. The cohort originated from two phase 2 randomized clinical trials of simtuzumab, a humanized monoclonal antibody targeting lysyl oxidase‐like 2 (LOXL2), which had negative results.5 Patients were assessed with paired liver biopsies and HPVG measurements (if cirrhotic at baseline) and were followed for outcomes. The study has a number of strengths, including a relatively large number of well‐defined patients with standardized follow‐up and protocol biopsies that have been centrally scored by a single liver pathologist, thereby limiting selection bias and observer variability. Additional strengths include the use of HPVG to measure changes in portal hypertension and image morphometry to quantify liver fibrosis. The study design, however, also has some intrinsic limitations, with strict inclusion and exclusion criteria limiting generalizability, limited length of follow‐up, and the possibility of altered lifestyle behavior of participants within the trial thereby changing the “natural history” of the disease. The 20% Rule (Fig. 1) Although the study was relatively short (96 weeks), a surprisingly high proportion of patients progressed or developed liver‐related complications: 22% (48/217) patients with baseline F3 fibrosis progressed to cirrhosis. Although sampling error cannot be excluded as a reason for apparent fibrosis progression, those patients with F3 fibrosis who progressed had lower NAFLD fibrosis scores and Fibrosis‐4 score (FIB‐4) and aspartate aminotransferase‐to‐platelet ratio index (APRI) levels than patients with cirrhosis at baseline, suggesting that these were different groups. In addition, 19% of patients with cirrhosis (50/258) had a liver‐related event. Similarly, Hui et al. found a 23% incidence of decompensation at 3 years in a small cohort of patients with NASH cirrhosis.6 Although NASH is thought to be a relatively indolent and slowly progressive disease, this suggests heterogeneity in disease progression with a subset of patients having an accelerated disease course. This is supported by a meta‐analysis of patients with NAFLD undergoing paired liver biopsies that found a similar proportion (21%) of patients were “rapid progressors” who developed F3/4 fibrosis from a baseline of no/minimal fibrosis over a mean of 5.9 years.7 Can we predict progression to cirrhosis or future decompensation? In the Sanyal study, simple demographics, such as age, sex, and body mass index, did not predict progression, although a trend was detected regarding type 2 diabetes mellitus and liver decompensation (hazard ratio 1.90; P = 0.07). Liver biopsy added limited guidance: although severe hepatocellular ballooning was associated with fibrosis progression, supporting its inclusion within the histological definition of NASH, neither baseline or change in steatosis, lobular inflammation, or the NAFLD activity score were predictive of disease progression or regression in patients with advanced fibrosis. Thus, as pointed out by the study authors, treatment endpoints for patients with advanced fibrosis/cirrhosis should focus on fibrosis and clinical outcomes. Surprisingly, pathologist staging (Ishak stage 4 [marked bridging] versus Ishak stage 3 [occasional bridging]) did not predict a greater risk of progression to c
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citationSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Self-citationSanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology · doi:10.1002/hep.30664 · Cited by 390 · cited 1×
“In this context, Sanyal and colleagues explore in this issue of Hepatology the progression of liver disease and predictors of fibrosis progression and decompensation, as well as potential monitoring strategies in 475 patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis or compensated cirrhosis.(4) N…”
BackgroundHarrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384
Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage
Siddiqui, M. S., Yamada, G., Vuppalanchi, R., Van Natta, M., Loomba, R., Guy, C., Brandman, D., Tonascia, J., Chalasani, N., Neuschwander-Tetri, B., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.12.031 · Cited by 272
Self-citation
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“When advanced fibrosis, cirrhosis, and portal hypertension have developed, the platelet count declines gradually over years (Loomba and Adams, 2019).”
BackgroundSelf-citationA Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
Self-citationNAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H.-M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 632
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 553
Loomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 357
Self-citationNon-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Self-citationThe fecal mycobiome in non-alcoholic fatty liver disease
Demir, M., Lang, S., Hartmann, P., Duan, Y., Martin, A., Miyamoto, Y., Bondareva, M., Zhang, X., Wang, Y., Kasper, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.029 · Cited by 197
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Ng, C. H., Xiao, J., Lim, W. H., Chin, Y. H., Yong, J. N., Tan, D. J. H., Tay, P., Syn, N., Foo, R., Chan, M., et al. (2022) · Hepatology · doi:10.1002/hep.32315 · Cited by 69
Self-citationTreatment Candidacy for Pharmacologic Therapies for NASH
Rowe, I. A., Wong, V. W.-S., & Loomba, R. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.005 · Cited by 41
Self-citationThe interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Metadata
- Authors
- Loomba, R., & Adams, L. A.
- Venue
- Hepatology
- Published
- 2019-11-29
- Volume
- 70
- Issue
- 6
- Pages
- 1885-1888
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2973208413
- Cited by
- 150
- References
- 6
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.